INTERVIEW: ImmunoGen prepares to capitalize on Kadcyla
This article was originally published in Scrip
Executive Summary
ImmunoGen is preparing to capitalize on US FDA approval in February for Kadcyla (ado trastuzumab emtansine) - the first approved cancer therapy that incorporates the Waltham, Massachusetts-based company's antibody-drug conjugate (ADC) technology.
You may also be interested in...
ImmunoGen’s Mirvetuximab Confidence Justified With Ovarian Cancer Win
The response rate, with five complete responses, exceeds known responses to standard-of-care chemotherapy in heavily pre-treated folate receptor alpha-high patients. A US FDA filing is on track for early 2022.
All Eyes On Amjevita, Amgen’s Humira Biosimilar And Sole 2023 Product Launch
The company launched Amjevita on the same day it announced fourth quarter 2022 earnings and provided 2023 guidance, upping the high-profile nature of the first-to-market US Humira biosimilar.
Gilead Keeps Focus On HIV, Long-Acting Drugs And Growth Through Oncology
Even with top-seller Biktarvy and its preventive therapy, Descovy, protected beyond this decade from generics, Gilead is investing aggressively in long-acting HIV candidates and its oncology pipeline.